The document discusses biotech funding trends from 2015-2025. It notes that biotech funding surged in 2015 according to reports from PWC and SVB. However, the biotech sector saw a 30% drop in stock prices in September 2015. It advises biotech companies to understand emerging trends like personalized medicine, nanomedicine, and cloud collaboration that could become major products by 2020-2025. The document also discusses focusing research on improving discovery through collaboration, increasing medical benefits through targeted therapies, and addressing cost effectiveness.

1. 2015 - S.C. @ www.nutopya.com
Biotech Finance

2. 2015 - S.C. @ www.nutopya.com
Funding trends
a-Average deal size b-Total fundings per stages
Biotech funding surges.
http://www.pwc.com/us/en/technology/assets/pwc-life-sciences-money-tee-q4-2014.pdf

3. 2015 - S.C. @ www.nutopya.com
Funding trends
Biopharma
Devices
Diagnostics
Tools
SVB (2015) Healthcare
Investments and Exits Report 2015.
https://www.svb.com/healthcare-report

4. 2015 - S.C. @ www.nutopya.com
Sector Outperformance
Mini bubble crack in September 2015
July 2015
Sept 2015
30% drop
Nasdaq Bio Indx S&P Bio Indx S&P 500Nasdaq
High level exit IPO
on stock market
allows VC to raise
fresh money for
their new funds
Investing
2015-2020
Divesting
2020-2025
(Depending on
stock market)

5. 2015 - S.C. @ www.nutopya.com
Understand your business
sector by 2020-2025
What trends will become
products ???
1 Technology Trigger
• Personalized Medicine
• Nanomedicine
• R&D Cloud Collaboration
4 Slope of Enlightenment
• Quality Process Management
• R&D Analytics
• Global Regulatory Management
• Laboratory Management System https://www.gartner.com/doc/2811930/hype-cycle-life-sciences-

6. 2015 - S.C. @ www.nutopya.com
Understand your business
sector by 2020-2025

7. 2015 - S.C. @ www.nutopya.com
Are you in line with new industry organization ???
Therefore there are three innovations lever the biomedical industry is focusing on:
1. Improve discovery throughout a structured collaborative effort
2. Increase therapeutic value and medical benefit by targeting the right population
3. Address cost effectiveness and demonstrate global healthcare expenses reduction
ATkearney (2013) Unleashing Pharma from the R&D Value Chain.
Understand your business
sector by 2020-2025